{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:59:32Z","timestamp":1777399172901,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2023YFC3041500"],"award-info":[{"award-number":["2023YFC3041500"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2021YFC2301805"],"award-info":[{"award-number":["2021YFC2301805"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371783"],"award-info":[{"award-number":["82371783"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JSGG20220226085800001"],"award-info":[{"award-number":["JSGG20220226085800001"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JSGG20220226090203006"],"award-info":[{"award-number":["JSGG20220226090203006"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jinf.2024.106208","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:02:36Z","timestamp":1718888556000},"page":"106208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants"],"prefix":"10.1016","volume":"89","author":[{"given":"Xiaohua","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiexiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juzhen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jinf.2024.106208_bib1","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.immuni.2021.11.016","article-title":"Antigenic drift: understanding COVID-19","volume":"54","author":"Yewdell","year":"2021","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.jinf.2024.106208_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jinf.2023.05.018","article-title":"Naive and breakthrough infections with BA.2, BA.5 and BF.7 variants provide poor cross protection against XBB related variants","volume":"87","author":"Yang","year":"2023","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.jinf.2024.106208_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"10.1016\/j.jinf.2024.106208_bib4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S2213-2600(21)00407-0","article-title":"Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?","volume":"9","author":"Milne","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jinf.2024.106208_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-023-01391-x","article-title":"Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.jinf.2024.106208_bib6","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S2666-5247(22)00384-6","article-title":"Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1","volume":"4","author":"Mykytyn","year":"2023","journal-title":"Lancet Microbe"},{"issue":"10","key":"10.1016\/j.jinf.2024.106208_bib7","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S1473-3099(23)00553-4","article-title":"Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against Omicron subvariants including EG.5","volume":"23","author":"Kaku","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2024.106208_bib8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","article-title":"Vaccine development for emerging infectious diseases","volume":"27","author":"Excler","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jinf.2024.106208_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00008-21","article-title":"Controlled human infection models to accelerate vaccine development","volume":"35","author":"Choy","year":"2022","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.jinf.2024.106208_bib10","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S2666-5247(22)00390-1","article-title":"Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials","volume":"4","author":"Yang","year":"2023","journal-title":"Lancet Microbe"},{"issue":"6585","key":"10.1016\/j.jinf.2024.106208_bib11","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1126\/science.abn1755","article-title":"COVID-19 vaccination: the road ahead","volume":"375","author":"Altmann","year":"2022","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jinf.2024.106208_bib12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41590-022-01248-5","article-title":"The humoral response and antibodies against SARS-CoV-2 infection","volume":"23","author":"Qi","year":"2022","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.jinf.2024.106208_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2024.106208_bib14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41392-022-01166-w","article-title":"Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.jinf.2024.106208_bib15","first-page":"275","article-title":"Are variant-specific vaccines warranted?","volume":"22","author":"Flemming","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.jinf.2024.106208_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.jinf.2024.106208_bib17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.immuni.2023.04.012","article-title":"Immunological imprinting: understanding COVID-19","volume":"56","author":"Koutsakos","year":"2023","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.jinf.2024.106208_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.it.2021.09.001","article-title":"Immune imprinting and SARS-CoV-2 vaccine design","volume":"42","author":"Wheatley","year":"2021","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2024.106208_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162192","article-title":"Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity","volume":"133","author":"Aguilar-Bretones","year":"2023","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.jinf.2024.106208_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jinf.2024.106208_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa2213082","article-title":"Bivalent Omicron BA.1-adapted BNT162b2 booster in adults older than 55 years","volume":"388","author":"Winokur","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jinf.2024.106208_bib22","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1056\/NEJMc2216233","article-title":"Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines","volume":"388","author":"Li","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jinf.2024.106208_bib23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1473-3099(23)00181-0","article-title":"SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster","volume":"23","author":"Wang","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2024.106208_bib24","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1056\/NEJMc2214916","article-title":"Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine","volume":"388","author":"Zou","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jinf.2024.106208_bib25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jinf.2024.106208_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41541-023-00708-9","article-title":"Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4\/BA.5) increases neutralization of matched Omicron variants","volume":"8","author":"Springer","year":"2023","journal-title":"NPJ Vaccin"},{"issue":"10377","key":"10.1016\/j.jinf.2024.106208_bib27","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(23)00129-0","article-title":"Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis","volume":"401","author":"Pan","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jinf.2024.106208_bib28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat Microbiol"},{"issue":"7","key":"10.1016\/j.jinf.2024.106208_bib29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jinf.2024.106208_bib30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4049\/jimmunol.170.2.686","article-title":"Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses","volume":"170","author":"Tangye","year":"2003","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.jinf.2024.106208_bib31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1084\/jem.106.6.835","article-title":"Predetermination by infection and by vaccination of antibody response to influenza virus vaccines","volume":"106","author":"Davenport","year":"1957","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.jinf.2024.106208_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4049\/jimmunol.1801149","article-title":"Original antigenic sin: how first exposure shapes lifelong anti-influenza virus immune responses","volume":"202","author":"Zhang","year":"2019","journal-title":"J Immunol"},{"issue":"29","key":"10.1016\/j.jinf.2024.106208_bib33","doi-asserted-by":"crossref","first-page":"17221","DOI":"10.1073\/pnas.1920321117","article-title":"Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies","volume":"117","author":"Arevalo","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6212","key":"10.1016\/j.jinf.2024.106208_bib34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1256427","article-title":"Antibody landscapes after influenza virus infection or vaccination","volume":"346","author":"Fonville","year":"2014","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jinf.2024.106208_bib35","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat Med"},{"issue":"6573","key":"10.1016\/j.jinf.2024.106208_bib36","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.abl8912","article-title":"Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates","volume":"374","author":"Corbett","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jinf.2024.106208_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41421-021-00350-6","article-title":"Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01","volume":"7","author":"Sun","year":"2021","journal-title":"Cell Discov"},{"issue":"73","key":"10.1016\/j.jinf.2024.106208_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq3511","article-title":"Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection","volume":"7","author":"Kaku","year":"2022","journal-title":"Sci Immunol"},{"issue":"75","key":"10.1016\/j.jinf.2024.106208_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq2427","article-title":"Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes","volume":"7","author":"Quandt","year":"2022","journal-title":"Sci Immunol"},{"issue":"3","key":"10.1016\/j.jinf.2024.106208_bib40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41422-023-00781-8","article-title":"Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection","volume":"33","author":"Gao","year":"2023","journal-title":"Cell Res"},{"issue":"7948","key":"10.1016\/j.jinf.2024.106208_bib41","first-page":"521","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","author":"Cao","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jinf.2024.106208_bib42","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jinf.2022.01.004","article-title":"Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees","volume":"84","author":"YangYang","year":"2022","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jinf.2024.106208_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.hlife.2023.07.002","article-title":"Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals","volume":"1","author":"Tan","year":"2023","journal-title":"hLife"},{"issue":"8","key":"10.1016\/j.jinf.2024.106208_bib44","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","article-title":"The antigenic anatomy of SARS-CoV-2 receptor binding domain","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"issue":"7993","key":"10.1016\/j.jinf.2024.106208_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","article-title":"Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting","volume":"625","author":"Yisimayi","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jinf.2024.106208_bib46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","article-title":"XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.jinf.2024.106208_bib47","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S1473-3099(23)00690-4","article-title":"Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination","volume":"24","author":"Stankov","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2024.106208_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","article-title":"From original antigenic sin to the universal influenza virus vaccine","volume":"39","author":"Henry","year":"2018","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2024.106208_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.immuni.2017.12.009","article-title":"Memory B cells that cross-react with group 1 and group 2 influenza A viruses are abundant in adult human repertoires","volume":"48","author":"McCarthy","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jinf.2024.106208_bib50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.chom.2019.01.010","article-title":"Persistent antibody clonotypes dominate the serum response to influenza over multiple years and repeated vaccinations","volume":"25","author":"Lee","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.jinf.2024.106208_bib51","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.immuni.2022.04.003","article-title":"Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins","volume":"55","author":"Wang","year":"2022","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.jinf.2024.106208_bib52","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41564-022-01155-3","article-title":"Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2","volume":"7","author":"Sun","year":"2022","journal-title":"Nat Microbiol"},{"issue":"6607","key":"10.1016\/j.jinf.2024.106208_bib53","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.abq2679","article-title":"ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies","volume":"377","author":"Low","year":"2022","journal-title":"Science"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:38:32Z","timestamp":1763177912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324001427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0163445324001427"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106208","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106208"}}